January 13, 2020

Cutaquig® (Subcutaneous Immunoglobulin): Now available through Canadian Blood Services

Dear Health Care Professional,

Cutaquig® (SCIG, Octapharma) is now available for your patients through CBS. Cutaquig® is a low viscosity (11.4 mPa*s at 20°C) subcutaneous immunoglobulin (SCIG) product available for patients throughout CBS jurisdiction. Cutaquig® has been extensively studied through well controlled clinical studies and established as an efficacious, well-tolerated and safe SCIG product. In February 2018, Health Canada approved cutaquig® for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID) who require immune globulin replacement therapy. Cutaquig® can be infused using the pump method of administration or using a syringe via manual rapid push. Health Canada recently approved the rapid push method of administration for cutaquig®, making it the only SCIG product in Canada with administration instructions for both pump and for manual rapid push included in the product monograph. Cutaquig® is available in 4 convenient vial sizes: 1g, 2g, 4g, and 8g.

Patient Support Program: We are pleased to offer a comprehensive patient support program (ProCare) for patients receiving cutaquig®. The program was developed to support patients with their SCIG treatment and make their infusion experience safe and easy. The program offers experienced nursing professionals to train patients on how to self-infuse their new SCIG treatment. The program also provides all supplies needed for their infusions and can be ordered free-of-charge with free delivery to their home or any designated location.

To enrol in the ProCare Infusion Training Program, patients will need to complete the ‘SCIG Infusion Training Program Form’ with their healthcare provider. If your patient requires only infusion supplies and does not require additional training, they will need to complete just the ProCare ‘Supply Request Form’ with their healthcare provider. Please note: if the patient is enrolled in the Infusion Training Program, the nurse can help fill in the ‘Supply Request Form’. For more information on the ProCare program or to obtain the training enrolment & supplies request forms, contact Octapharma Canada at info.canada@octapharma.com.
**Important Safety Information:** As with all SCIG products cutaquig® is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For complete prescribing information, refer to the cutaquig® Product Monograph found [here](#). For additional information on cutaquig® or to request an in-service, please contact our medical information service by email [medinfo.canada@octapharma.com](mailto:medinfo.canada@octapharma.com) or call 1-888-438-0488.

Octapharma’s commitment to patients requiring IG therapy is demonstrated by our unique immunoglobulin product portfolio which offers different formulations, concentrations and routes of administration in liquid, ready-to-use solutions for healthcare professionals and their patients around the world. We are confident that cutaquig® will become an important therapeutic option for your patients who require SCIG treatment. We also trust the available ProCare service will assist in training new SCIG patients quickly and help them stay on treatment with helpful value added services.

Sincerely,

Sri Adapa  
General Manager

References: 1. cutaquig® Canadian Product Monograph, August 26, 2019